

# Contents of Volume

## No. 1

*H. Ochiai, K. Kumura and Y. Minamishima (Japan)*

Murine cytomegalovirus DNA polymerase: purification, characterization and role in the antiviral activity of acyclovir

1

*E.-S. Huang, J.D. Benson, S.-m. Huong, B. Wilson and C. van der Horst (U.S.A.)*

Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection

17

*B.E. Gilbert, P.R. Wyde, M.W. Ambrose, S.Z. Wilson and V. Knight (U.S.A.)*

Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats

33

*J.-C. Lin, J. Reefschräger, G. Herrmann and J.S. Pagano (F.R.G., U.S.A.)*

Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1- $\beta$ -D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication

43

*D. Kitchington, S. Galpin, J.W. Jaroszewski, K. Ghosh, C. Subasinghe and J.S. Cohen (Denmark, U.K., U.S.A.)*

A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1

53

*D.L. Barnard, J.H. Huffman, J.L.B. Morris, S.G. Wood, B.G. Hughes and R.W. Sidwell (U.S.A.)*

Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus

63

*B. Lidin and E.W. Lamon (U.S.A.)*

Differential effects of human recombinant interferons on the expression of two early gene products of Epstein-Barr virus

79

Letters to the Editor

91

## No. 2

*R.S. Ostrow, K.M. Forslund, R.C. McGlennen, D.P. Shaw, P.M. Schlievert, M.A. Ussery, J.W. Huggins and A.J. Faras (U.S.A.)*

Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus

99

*R.C. Gehrz, C.M. Curtis, M. Nelson and B.E. Kari (U.S.A.)*

A combination of human cytomegalovirus (HCMV)-specific murine monoclonal antibodies exhibits synergistic antiviral activity in vitro

115

*H. Machida, K. Ijichi and J. Takezawa (Japan)*

Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice

133

- A.D. Idowu, E.B. Fraser-Smith, K.L. Poffenberger and R.C. Herman (U.S.A.)  
Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo 145

- M.D. Trousdale, J.L. Law, F.A. Yarber, K.A. Watanabe and J.J. Fox (U.S.A.)  
Evaluation of 1-(2'-deoxy-2'-fluoro- $\beta$ -D-arabinofuranosyl)-5-ethyluracil in a rabbit model of herpetic keratitis 157

- S.D., O'Marro, J.A. Armstrong, C. Asuncion, L. Gueverra and M. Ho (U.S.A.)  
The effect of combinations of ampliten and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro 169

### No. 3

- J.W. Lown (Canada)  
Lexitropsins in antiviral drug development (Mini-Review) 179

- C. McGuigan, C. Nickson, T.J. O'Connor and D. Kinchington (U.K.)  
Synthesis and anti-HIV activity of some novel lactyl and glycolyl phosphate derivatives 197

- S.J. Sperber, B.V. Smith and F.G. Hayden (U.S.A.)  
Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine 213

- J.D. Morrey, J.R. Mead, R.P. Warren, K.M. Okleberry, R.A. Burger and R.W. Sidwell (U.S.A.)  
Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice 223

- M. Lebwohl, S. Sacks, M. Conant, J. Connor, J.M. Douglas, Jr., L. Eron, S. Marlowe, J. Mendelson, V. Chen, P. Bradstreet, D. Fedorczyk, J.R. Trout and T. Plasse (Canada, U.S.A.)  
Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis 235

### No. 4

#### Mini-Symposium – HIV Infections

- M. Baba, S. Shigeta, H. Tanaka, T. Miyasaka, M. Ubasawa, K. Umezu, R.T. Walker, R. Pauwels and E. De Clercq (Belgium, Japan, U.K.)  
Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives 245

- J.A. Martin (U.K.)  
Recent advances in the design of HIV proteinase inhibitors 265

- G. Degols, J.-P. Leonetti, P. Milhaud, N. Mechti and B. Lebleu (France)  
Antisense inhibitors of HIV: problems and perspectives 279

- C.-F. Perno, R. Yarchoan, J. Balzarini, A. Bergamini, G. Milanese, R. Pauwels, E. De Clercq, G. Rocchi and R. Calio (Belgium, Italy, U.S.A.)  
Different pattern of activity of inhibitors of the human immunodeficiency virus in

	351
lymphocytes and monocyte/macrophages	289
<i>R.T. Schooley (U.S.A.)</i>	
Challenges in the clinical development of antiretroviral drugs	305
<b>Research Articles</b>	
<i>C., McGuigan, R.N. Pathirana, N. Mahmood, K.G. Devine and A.J. Hay (U.K.)</i>	
Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT	311
<i>K. Hayashi, H. Nishino, A. Niwayama, K. Shiraki and A. Hiramatsu (Japan)</i>	
Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication	323
<i>D.J. Volsky, G. Li, N. Hamblet, B. Bolsky, R.S. Decker, M.G. Pellegrino and M.J. Potash (U.S.A.)</i>	
Evaluation of multiple parameters of HIV-1 replication cycle in testing of AIDS drugs in vitro	335
Contents of volume 17	349
Author Index	353
Subject Index	357